Researchers have discovered a genetic adaptation in high-altitude animals, like yaks, that could unlock new strategies for treating brain diseases such as multiple sclerosis (MS). The key lies in a gene called Retsat, found in animals thriving on oxygen-deprived plateaus, which appears to protect the brain against damage caused by low oxygen levels.
The Evolutionary Advantage of High-Altitude Brains
Animals adapted to high altitudes—yaks, antelopes, and others—possess a unique version of the Retsat gene. Unlike their lowland counterparts, these animals maintain healthy white matter in the brain, despite living in environments where oxygen is scarce. This observation prompted scientists to investigate whether the mutation provides direct brain protection rather than simply improving lung function.
Why this matters: The brain’s white matter—nerve fibers that enable communication between brain regions—is vulnerable to oxygen deprivation. Disruptions to white matter can lead to neurological conditions like cerebral palsy in newborns and worsen symptoms in MS patients. The Retsat gene may provide a natural solution for protecting or repairing this crucial tissue.
How the Yak Gene Protects the Brain
Experiments on mice revealed that the Retsat mutation significantly improves brain function under low-oxygen conditions. Young mice with the genetic adaptation performed better in learning, memory, and social behavior tests and exhibited increased myelin production—the fatty substance insulating nerve fibers.
The Mechanism: Retsat facilitates the conversion of a vitamin A-related molecule (ATDR) into its active form (ATDRA). This conversion triggers the maturation of oligodendrocytes, the brain cells responsible for producing myelin. Injecting ATDR and ATDRA directly into mice exposed to low oxygen reduced myelin damage, and administering ATDR to mice with MS-like brain damage improved symptoms.
The Path to Human Therapies
While the findings are promising, translating this research into human treatments will require careful study. Existing MS therapies focus on slowing disease progression by suppressing the immune system, but repairing existing nerve damage remains a major challenge.
Challenges and Next Steps: Previous attempts to stimulate oligodendrocyte production using similar molecular pathways resulted in severe side effects, highlighting the need for caution. Researchers must determine safe and effective concentrations of ATDR and ATDRA before clinical trials can begin.
“It’s beautiful science, but there’s a big step before this gets to humans,” notes Anna Williams, a neurologist at the University of Edinburgh.
If successful, this approach could extend beyond MS to treat other neurodegenerative diseases and even stroke, offering a revolutionary way to repair brain damage by harnessing the evolutionary adaptations of animals like yaks. The study underscores the potential of nature-inspired solutions for complex medical challenges.
